Notícias e Atividades da Teva Pharmaceutical Industries

Teva Pharmaceutical Industries é uma das ...

• Forbes Global 2000 (#935);
• TOB Iconic 10,000.

Teva Pharmaceutical Industries é uma empresa listada sob o símbolo TEVA (IL).

Teva Pharmaceutical Industries tem presença direta em 18 países.

Teva Pharmaceutical Industries possui 19 subsidiárias incluindo Medis Germany, Pliva e Teva ANZ.

Veja o organograma con seus 121 executivos principais

Biografias mais buscadas da Teva Pharmaceutical Industries

• Richard Francis, Director, President and Chief Executive Officer
• Perry Nisen, Director
• Tal Zaks, Director

Criar um alerta
para seguir os movimentos de executivos da Teva Pharmaceutical Industries.

Teva Pharmaceutical Industries possui 1.836 concorrentes concorrentes Pfizer (Estados Unidos), Sanofi (França) e Johnson & Johnson (Estados Unidos).

Popular M&A news in Farmacêutica

• Supernus Pharmaceuticals has announced the acquisition of Sage Therapeutics  (publicado em 16 de junho de 2025).
• Juvenescence acaba de anunciar uma arrecadação de fundos de 76 milhões de dólares. (publicado em 22 de maio de 2025).
• Kincell Bio acaba de anunciar uma arrecadação de fundos de 22 milhões de dólares. (publicado em 22 de maio de 2025).

Outros contatos sugeridos na indústria do Farmacêutica

• Estelle Vester-Blokland - Senior Vice President, Medical and Head, International Markets da Bristol-Myers Squibb
• Amanda Moore - Vice President, Program Leadership and Clinical Operations da Abeona Therapeutics
• Jean-Michel Demeure - Vice President, Finance Global Operations da Sanofi

Saiba mais sobre a indústria do Farmacêutica

Últimos comunicados de imprensa de Teva Pharmaceutical Industries

• Teva to Present at Jefferies Global Healthcare Conference and Goldman Sachs Global Healthcare Conference in June
• Teva Reaffirms “Pivot to Growth” Strategy Progress with Launch of Acceleration Phase at 2025 Innovation and Strategy Day
• Teva Celiac Disease Candidate Granted Fast Track Designation by US FDA
• Teva and Biolojic Design Initiate IND-enabling Studies of BD9, a Multibody Designed to Explore the Treatment of Atopic Dermatitis and Asthma
• Teva Announces $2,000,000,000 (Equivalent) Debt Tender Offers For Notes Due 2026-2031
• Teva Announces Increase of the Maximum Tender Amount of its Debt Tender Offer and Increases to Pool Tender Caps for Pool 2 Notes and Pool 3 Notes
• Teva Announces Successful Upsizing and Pricing of $2,300,000,000 (Equivalent) Senior Notes; Proceeds to Repay Existing Debt
• Fitch Ratings Agency Upgrades Teva Rating to BB+ Recognizing Successful Execution of Its Pivot to Growth Strategy
• Teva Announces Launch of $2,000,000,000 (Equivalent) Offering of Senior Notes
• Moody's Investor Services Upgrades Teva Amid Continued Success of Pivot to Growth Strategy
• View more press releases Close

Redes sociais sobre Teva Pharmaceutical Industries

• Teva Pharmaceutical Industries na Wikipedia, Google News e Yahoo Finance
• Teva Pharmaceutical Industries na LinkedIn, Twitter e YouTube